Clopidogrel (plavix)

AJNR Am J Neuroradiol. 2011 Dec;32(11):2002-4. doi: 10.3174/ajnr.A2913. Epub 2011 Dec 1.

Abstract

Clopidogrel is an inhibitor of platelet aggregation, indicated for the prevention of ischemic stroke and in-stent thrombosis. However, it has a number of drawbacks, including an increased risk of hemorrhage; a clinical effect that is slow in onset and irreversible; a genetically determined variability in its clinical potency; and interactions with other commonly administered drugs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Clopidogrel
  • Dose-Response Relationship, Drug
  • Hemorrhage / chemically induced*
  • Hemorrhage / prevention & control*
  • Humans
  • Platelet Aggregation Inhibitors / administration & dosage
  • Stroke / prevention & control*
  • Ticlopidine / administration & dosage
  • Ticlopidine / adverse effects
  • Ticlopidine / analogs & derivatives*

Substances

  • Platelet Aggregation Inhibitors
  • Clopidogrel
  • Ticlopidine